scPharmaceuticals Inc. (SCPH)

NASDAQ: SCPH · IEX Real-Time Price · USD
6.93
+0.06 (0.87%)
Mar 21, 2023, 4:30 PM EDT - Market closed
0.87%
Market Cap 249.09M
Revenue (ttm) n/a
Net Income (ttm) -34.91M
Shares Out 35.94M
EPS (ttm) -1.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 168,465
Open 6.92
Previous Close 6.87
Day's Range 6.73 - 7.08
52-Week Range 3.68 - 10.38
Beta 0.22
Analysts Buy
Price Target 16.93 (+144.3%)
Earnings Date Mar 22, 2023

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2017
Employees 26
Stock Exchange NASDAQ
Ticker Symbol SCPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is $16.93, which is an increase of 144.30% from the latest price.

Price Target
$16.93
(144.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

Management to host conference call and webcast at 4:30 p.m. ET

6 days ago - GlobeNewsWire

scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference

BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

3 weeks ago - GlobeNewsWire

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

BURLINGTON, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

1 month ago - GlobeNewsWire

Recent Price Trend in scPharmaceuticals, Inc. (SCPH) is Your Friend, Here's Why

scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made...

1 month ago - Zacks Investment Research

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing pr...

1 month ago - GlobeNewsWire

scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

BURLINGTON, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

1 month ago - GlobeNewsWire

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

Commercial launch planned for February 20, 2023 Commercial launch planned for February 20, 2023

1 month ago - GlobeNewsWire

scPharmaceuticals, Inc. (SCPH) Is a Great Choice for 'Trend' Investors, Here's Why

scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made...

2 months ago - Zacks Investment Research

What Makes scPharmaceuticals, Inc. (SCPH) a New Buy Stock

scPharmaceuticals, Inc. (SCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?

Here is how scPharmaceuticals, Inc. (SCPH) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Wall Street Analysts See a 164% Upside in scPharmaceuticals, Inc. (SCPH): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 163.7% in scPharmaceuticals, Inc. (SCPH). While the effectiveness of this highly sought-after metric is questio...

3 months ago - Zacks Investment Research

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role Appointment brings more than 20 years of life sciences finance leadership experience to the CFO rol...

3 months ago - GlobeNewsWire

scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event

BURLINGTON, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

3 months ago - GlobeNewsWire

scPharmaceuticals Announces Pricing of $50 Million Public Offering

BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

4 months ago - GlobeNewsWire

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

BURLINGTON, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

4 months ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure

4 months ago - GlobeNewsWire

scPharmaceuticals to Participate in the Jefferies London Healthcare Conference

BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

4 months ago - GlobeNewsWire

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

5 months ago - GlobeNewsWire

scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval

scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.

5 months ago - Zacks Investment Research

Why Is scPharmaceuticals (SCPH) Stock in the Spotlight Today?

There were not just one, but two press releases from scPharmaceuticals (NASDAQ: SCPH) this morning. Apparently, the U.S. Food and Drug Administration (FDA) approved Furoscix.

5 months ago - InvestorPlace

UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide

5 months ago - GlobeNewsWire

scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree

Funds to be used to facilitate U.S. commercial launch of FUROSCIX® Funds to be used to facilitate U.S. commercial launch of FUROSCIX®

5 months ago - GlobeNewsWire

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide

5 months ago - GlobeNewsWire

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX® (furosemide injection) at home Presentations highlight the sign...

6 months ago - GlobeNewsWire

scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

BURLINGTON, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to opti...

7 months ago - GlobeNewsWire